Hu14.18K322A
Showing 1 - 25 of >10,000
Pretreatment Anti-Therapeutic Antibodies in Patients Treated
Completed
- Ewing Family of Tumors
- +3 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Nov 4, 2020
Neuroblastoma Trial in Memphis (biological, drug, other, device)
Completed
- Neuroblastoma
- Humanized anti-GD2 antibody
- +4 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Nov 14, 2018
Bullous Pemphigoid Trial in Worldwide (biological, other, drug)
Recruiting
- Bullous Pemphigoid
- efgartigimod PH20 SC
- +2 more
-
Fountain Valley, California
- +24 more
Jul 27, 2022
Plaque Psoriasis Trial in Canada, United States (Roflumilast Cream 0.3%, Roflumilast Cream 0.15%, Vehicle Cream)
Completed
- Plaque Psoriasis
- Roflumilast Cream 0.3%
- +2 more
-
Beverly Hills, California
- +29 more
Aug 31, 2022
Brodalumab in Plaque Psoriasis to Understand Impact on Quality
Recruiting
- Psoriasis
- Brodalumab
- Matched cohort
-
Calgary, Alberta, Canada
- +33 more
Oct 8, 2022
Ganglioneuroblastoma, Nodular, Neuroblastoma Trial in Worldwide (Dinutuximab, Irinotecan, Isotretinoin)
Active, not recruiting
- Ganglioneuroblastoma, Nodular
- Neuroblastoma
- Dinutuximab
- +4 more
-
Mesa, Arizona
- +77 more
Aug 17, 2022
Generalized Myasthenia Gravis Trial in Worldwide (efgartigimod PH20 SC)
Active, not recruiting
- Generalized Myasthenia Gravis
- efgartigimod PH20 SC
-
Carlsbad, California
- +46 more
Jul 5, 2022
Melanoma Trial in Madison (hu14.18-IL2)
Completed
- Melanoma
-
Madison, WisconsinUniversity of Wisconsin Hospitals and Clinics
Nov 13, 2019
Multiple Sclerosis, Relapsing-Remitting Trial in Worldwide (GA Depot, Placebo)
Active, not recruiting
- Multiple Sclerosis, Relapsing-Remitting
- GA Depot
- Placebo
-
Birmingham, Alabama
- +111 more
Aug 11, 2021
Neuroblastoma Trial in Los Angeles (Dinutuximab with Chemotherapy)
Not yet recruiting
- Neuroblastoma
- Dinutuximab with Chemotherapy
-
Los Angeles, CaliforniaChildrens Hospital Los Angeles
Jun 13, 2022
Pemphigus Vulgaris, Pemphigus Foliaceus Trial in Worldwide (efgartigimod PH20 SC, prednisone)
Recruiting
- Pemphigus Vulgaris
- Pemphigus Foliaceus
- efgartigimod PH20 SC
- prednisone
-
Birmingham, Alabama
- +120 more
Dec 22, 2022
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma Trial in Worldwide
Active, not recruiting
- Localized Resectable Neuroblastoma
- +5 more
- Aldesleukin
- +6 more
-
Birmingham, Alabama
- +196 more
Dec 30, 2022
AF Analysis Software in AF Rhythm Monitoring
Recruiting
- Atrial Fibrillation
- Atrial Fibrillation Paroxysmal
- ECG/PPG monitoring
-
Beijing, Beijing, China
- +1 more
Oct 13, 2022
Generalized Myasthenia Gravis Trial in Worldwide (efgartigimod PH20 SC, efgartigimod IV)
Completed
- Generalized Myasthenia Gravis
- efgartigimod PH20 SC
- efgartigimod IV
-
Carlsbad, California
- +46 more
Jan 31, 2022
Pemphigus Vulgaris, Pemphigus Foliaceus Trial in Worldwide (biological, other, drug)
Recruiting
- Pemphigus Vulgaris
- Pemphigus Foliaceus
- efgartigimod PH20 SC
- +2 more
-
Birmingham, Alabama
- +130 more
Dec 22, 2022
High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma Trial in Worldwide (Dinutuximab, Eflornithine
Recruiting
- High Risk Neuroblastoma
- +2 more
- Dinutuximab
- +4 more
-
Birmingham, Alabama
- +141 more
Dec 28, 2022
Prostate Cancer, Magnetic Resonance Imaging, Population at Risk Trial in Lake Success (Bi-parametric MRI)
Recruiting
- Prostate Cancer
- +2 more
- Bi-parametric MRI
-
Lake Success, New YorkCynthia Knauer
Aug 26, 2022
Lung Cancer, Lung; Node Trial (CT scans 2D Reconstruction, CT scans 2D plus 3D Reconstruction)
Not yet recruiting
- Lung Cancer
- Lung; Node
- CT scans 2D Reconstruction
- CT scans 2D plus 3D Reconstruction
- (no location specified)
Jan 27, 2023
Breast Cancer Trial in Worldwide (trastuzumab, docetaxel, lapatinib ditosylate)
Active, not recruiting
- Breast Cancer
- trastuzumab
- +3 more
-
Anchorage, Alaska
- +257 more
Feb 28, 2022
Breast Cancer Female Trial in São Paulo (adjuvant ultra-hypofractionated radiotherapy)
Completed
- Breast Cancer Female
- adjuvant ultra-hypofractionated radiotherapy
-
São Paulo, BrazilInstituto de Pesquisa Prevent Senior
Apr 30, 2023
Seborrheic Dermatitis Trial in Canada, United States (ARQ-154 - Active, ARQ-154 Vehicle)
Completed
- Seborrheic Dermatitis
- ARQ-154 - Active
- ARQ-154 Vehicle
-
Scottsdale, Arizona
- +52 more
Aug 4, 2022